Ligand Pharmaceuticals Incorporated (LGND) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Ligand Pharmaceuticals Incorporated (LGND) closed at USD 294.99 on 2026-10-14, a change of +56.2 % over the past year, with a market capitalization of USD 5.95B.

Ligand Pharmaceuticals Incorporated recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Ligand Pharmaceuticals Incorporated key figures

Previous close

USD 294.99 (2026-10-14)

1-year change

+56.2 %

Market cap

USD 5.95B

Enterprise value

USD 5.72B

P/E ratio (trailing)

31.45

P/E ratio (forward)

24.98

EPS (trailing)

9.49

EPS (forward)

11.95

PEG ratio

1.53

Price to book

6.15

Revenue growth

33.7 %

Earnings growth

825 %

Dividend per share (trailing)

0.00

Short ratio

10.56

Employees

47

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Ligand Pharmaceuticals Incorporated and compare it with other stocks.